Cargando…

Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database

Ketamine and dextromethorphan are widely abused psychoactive substances. Inhibition of N‐methyl‐d‐aspartate receptors (NMDARs) results in neurobehavioural effects including hallucinations, “out of body” sensations and dissociative effects. However, little is known about a possible extended addictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Revol, Bruno, Lapeyre‐Mestre, Maryse, Fouilhé Sam‐Laï, Nathalie, Jouanjus, Emilie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796803/
https://www.ncbi.nlm.nih.gov/pubmed/35665950
http://dx.doi.org/10.1111/bcp.15430
_version_ 1784860570707558400
author Revol, Bruno
Lapeyre‐Mestre, Maryse
Fouilhé Sam‐Laï, Nathalie
Jouanjus, Emilie
author_facet Revol, Bruno
Lapeyre‐Mestre, Maryse
Fouilhé Sam‐Laï, Nathalie
Jouanjus, Emilie
author_sort Revol, Bruno
collection PubMed
description Ketamine and dextromethorphan are widely abused psychoactive substances. Inhibition of N‐methyl‐d‐aspartate receptors (NMDARs) results in neurobehavioural effects including hallucinations, “out of body” sensations and dissociative effects. However, little is known about a possible extended addictive class effect linked to pharmacologically‐related amino‐adamantane derivatives (e.g., amantadine and memantine). Using a quasi‐Bayesian analytic method, we investigated the potential association between the use of approved NMDAR antagonists (i.e., dextromethorphan, ketamine, amantadine and memantine) and the reporting of drug abuse and dependence in the WHO pharmacovigilance database (VigiBase®), which includes >21 million individual case safety reports collected from >130 countries. This disproportionality analysis identified a significant association for all investigated drugs: dextromethorphan (IC = 3.03 [2.97–3.09]), ketamine (IC = 1.70 [1.57–1.83]), amantadine (IC = 0.21 [0.06–0.35]) and memantine (IC = 0.27 [0.13–0.40]), suggesting a class effect for drug abuse and dependence. This first signal requires further investigations, but health professionals need to be alert to the potential of abuse of NMDAR antagonists, especially in the current “opioid epidemic” context, due to their growing interest as non‐opioid antinociceptive drugs.
format Online
Article
Text
id pubmed-9796803
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97968032023-01-04 Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database Revol, Bruno Lapeyre‐Mestre, Maryse Fouilhé Sam‐Laï, Nathalie Jouanjus, Emilie Br J Clin Pharmacol Short Communications Ketamine and dextromethorphan are widely abused psychoactive substances. Inhibition of N‐methyl‐d‐aspartate receptors (NMDARs) results in neurobehavioural effects including hallucinations, “out of body” sensations and dissociative effects. However, little is known about a possible extended addictive class effect linked to pharmacologically‐related amino‐adamantane derivatives (e.g., amantadine and memantine). Using a quasi‐Bayesian analytic method, we investigated the potential association between the use of approved NMDAR antagonists (i.e., dextromethorphan, ketamine, amantadine and memantine) and the reporting of drug abuse and dependence in the WHO pharmacovigilance database (VigiBase®), which includes >21 million individual case safety reports collected from >130 countries. This disproportionality analysis identified a significant association for all investigated drugs: dextromethorphan (IC = 3.03 [2.97–3.09]), ketamine (IC = 1.70 [1.57–1.83]), amantadine (IC = 0.21 [0.06–0.35]) and memantine (IC = 0.27 [0.13–0.40]), suggesting a class effect for drug abuse and dependence. This first signal requires further investigations, but health professionals need to be alert to the potential of abuse of NMDAR antagonists, especially in the current “opioid epidemic” context, due to their growing interest as non‐opioid antinociceptive drugs. John Wiley and Sons Inc. 2022-06-14 2022-11 /pmc/articles/PMC9796803/ /pubmed/35665950 http://dx.doi.org/10.1111/bcp.15430 Text en © 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Communications
Revol, Bruno
Lapeyre‐Mestre, Maryse
Fouilhé Sam‐Laï, Nathalie
Jouanjus, Emilie
Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database
title Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database
title_full Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database
title_fullStr Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database
title_full_unstemmed Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database
title_short Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database
title_sort association between nmdar antagonists, drug abuse and dependence: a disproportionality analysis from the who pharmacovigilance database
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796803/
https://www.ncbi.nlm.nih.gov/pubmed/35665950
http://dx.doi.org/10.1111/bcp.15430
work_keys_str_mv AT revolbruno associationbetweennmdarantagonistsdrugabuseanddependenceadisproportionalityanalysisfromthewhopharmacovigilancedatabase
AT lapeyremestremaryse associationbetweennmdarantagonistsdrugabuseanddependenceadisproportionalityanalysisfromthewhopharmacovigilancedatabase
AT fouilhesamlainathalie associationbetweennmdarantagonistsdrugabuseanddependenceadisproportionalityanalysisfromthewhopharmacovigilancedatabase
AT jouanjusemilie associationbetweennmdarantagonistsdrugabuseanddependenceadisproportionalityanalysisfromthewhopharmacovigilancedatabase